• search
For Quick Alerts
For Daily Alerts

Drug targets defective protein that causes cystic fibrosis

By Abdul Nisar

London, Nov 18 (ANI): A new small study has shown that an investigational drug targeting a defective protein that causes cystic fibrosis (CF) can improve lung function.

The investigational drug, VX-770, appeared to improve function of what is known as CFTR-the faulty protein responsible for CF and is among the first compounds being developed for CF that specifically targets the root cause of cystic fibrosis.

Patients who took VX-770 for 28 days showed improvements in several key indicators of cystic fibrosis, including lung function, nasal potential difference measurements and sweat chloride levels.

"Patients with CF have a defective protein in chloride channels in lung cells that, in effect, causes a door to shut too tightly, ultimately leading to severe infections in the lung" said Steven M. Rowe, assistant professor of medicine at the University of Alabama at Birmingham and lead investigator at the UAB site.

"The data suggest that the drug seems to improve the function of the protein, so that the door opens and closes more properly," he added.

Investigators studied 39 patients with CF in the trial who had a specific mutation in the gene known to cause CF with the primary objective of demonstrating the safety and tolerability of VX-770. All patients in the trial completed use of the study drug, and adverse events were similar to placebo.

VX-770 is currently in Phase 3 clinical trials for cystic fibrosis, and, pending data from these studies, Vertex anticipates submitting a new drug application to the FDA in the second half of 2011.

CF is a fatal genetic disease that affects 70,000 people worldwide. It is caused by a genetic mutation that causes life-threatening lung infections and premature death.

Findings are published in the New England Journal of Medicine. (ANI)

For Daily Alerts
Get Instant News Updates
Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more